logo
← Back to all media

IN BRIEF: International Biotechnology notes Pfizer buys investee

International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Notes it has stake in Biohaven Pharmaceutical Holding Co Ltd, a pharmaceutical firm which Pfizer Inc has agreed to acquire for USD11.6 billion. Biohaven is International Biotechnology's seventh-largest holding, representing 4.1% of its net asset value as of March 31. International Biotechnology co-manager Ailsa Craig says deal represents sign "Covid cash" is being put to use on M&A in pharmaceutical sector. The trust notes Biohaven is not a constituent of its benchmark Nasdaq Biotech Index. Biohaven is listed on the New York Stock Exchange.

Published on 10th May 2022

Science background with molecule or atom Abstract structure for Science or medical background
Science background with molecule or atom Abstract structure for Science or medical background

Disclaimer

The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the UK.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).


I do not accept →